title: Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS).
abstract: BACKGROUND
  From 20% to 40% of all patients commencing dialysis are diabetic. The quality of glycemic control is an important determinant of outcome. The aims of this study were to investigate the use of the continuous glucose monitoring system (CGMS) to assess overall 24-hour glycemic control and the effects of both nonglucose containing and more biocompatible alternative peritoneal dialysis solutions in insulin-treated continuous ambulatory peritoneal dialysis (CAPD) patients.
  
  
  METHODS
  We studied 8 insulin treated diabetic CAPD patients. A CGMS probe was inserted [allowing automatic measurement of interstitial fluid (ISF) glucose every 5 minutes, for a 72-hour period]. The patients were then allowed home with CGMS monitoring to assess the effect on glycemic control of three differing peritoneal dialysis regimes. Phase 1 consisted of three exchanges of 1.36% glucose and one of 3.86% glucose, utilizing a lactate/bicarbonate buffer. Phase 2 was identical but used lactate-buffered fluid alone. Phase 3 utilized a minimally glycemic combination of one amino acid, one icodextrin, and two 1.36% glucose lactate/bicarbonate-containing exchanges.
  
  
  RESULTS
  ISF glucose measured by CGMS correlated well with venous glucose measurements (r2 = 0.82, P < 0.0001). There was a statistically significant difference in the mean ISF glucose between all three phases (P < 0.0001). The variation in glycemic control was tighter during phase 3 [mean coefficient of variation (CV) 0.21 +/- 0.03].
  
  
  CONCLUSIONS
  CGMS appears to be a clinically useful tool to gain additional insights into the glycemic control of diabetic CAPD patients. More biocompatible and nonglucose-containing dialysis fluids seem to be associated with improvements in glycemic control in this group of patients.
authors.affiliation: Department of Renal Medicine, andDiabetes Unit, South Derbyshire Acute Hospitals Trust, Derby, United Kingdom.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Marshall
authors.forename: Peter
authors.initials: P
authors.lastname: Jennings
authors.forename: Adrian
authors.initials: A
authors.lastname: Scott
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Fluck
authors.forename: Christopher W
authors.initials: CW
authors.lastname: McIntyre
mesh_terms: D000328:Adult; D000368:Aged; D001639:Bicarbonates; D001786:Blood Glucose / Q000032:analysis*; D002021:Buffers; D003404:Creatinine / Q000378:metabolism; D003920:Diabetes Mellitus / Q000097:blood* / Q000188:drug therapy; D015314:Dialysis Solutions / Q000627:therapeutic use; D005936:Glucans / Q000627:therapeutic use; D005947:Glucose / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000077607:Icodextrin; D007328:Insulin / Q000627:therapeutic use; D019344:Lactic Acid; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods / Q000592:standards; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010537:Peritoneum / Q000378:metabolism; D014680:Veins
chemical_list: D001639:Bicarbonates; D001786:Blood Glucose; D002021:Buffers; D015314:Dialysis Solutions; D005936:Glucans; D007004:Hypoglycemic Agents; D007328:Insulin; D000077607:Icodextrin; D019344:Lactic Acid; D003404:Creatinine; D005947:Glucose